Table 3.
Distribution of therapy regimens dependent on type of CIN (n = 48).
| Type of CIN | Typical CIDP (n = 31 patients) | MADSAM (n = 9 patients) | Atypical CIDP (n = 3 patients) | PDN (n = 5 patients) | p value | ||||
|---|---|---|---|---|---|---|---|---|---|
| Therapy regimen | Regimens/type of CIN* % | Regimens/type of CIN* % | Regimens/type of CIN* % | Regimens/type of CIN* % | |||||
| CYP | 27 | 87 | 5 | 56 | 1 | 33 | 1 | 20 | <0.01 |
| RTX | 11 | 36 | 8 | 89 | 2 | 67 | 4 | 80 | 0.02 |
| BTZ | 8 | 26 | 2 | 22 | 1 | 33 | 1 | 20 | 0.97 |
*
Number of therapy regimens used per number of patients in each type of CIN, indicating inhomogenous use of drugs in different types of CIN.
BTZ, bortezomib; CIDP, chronic inflammatory demyelinating polyneuropathy; CIN, chronic immune-mediated sensorimotor neuropathies; CYP, cyclophosphamide; MADSAM, Lewis-Sumner syndrome/multifocal acquired demyelinating sensory and motor neuropathy; PDN, paraproteinemic demyelinating neuropathy; RTX, rituximab.